Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer

BACKGROUND: Peritoneal carcinomatosis (PC) represents an unfavourable prognostic factor for patients with gastric cancer (GC). Intraperitoneal treatment with the bispecific and trifunctional antibody catumaxomab (EpCAM, CD3), in addition to systemic chemotherapy, could improve elimination of PC. MET...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Knödler, Maren, Körfer, Justus, Kunzmann, Volker, Trojan, Jörg, Daum, Severin, Schenk, Michael, Kullmann, Frank, Schroll, Sebastian, Behringer, Dirk, Stahl, Michael, Al-Batran, Salah-Eddin, Hacker, Ulrich, Ibach, Stefan, Lindhofer, Horst, Lordick, Florian
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6070920/
https://ncbi.nlm.nih.gov/pubmed/29988111
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0150-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars